Overview

Study of LY2157299 in Japanese Participants With Cancer

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and side effects of LY2157299 in Japanese participants with advanced cancer or cancer that has spread to other parts of the body.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company